mRNA Technology: What Comes After the COVID Vaccine

The COVID-19 vaccines developed by Moderna and BioNTech/Pfizer were not, in any meaningful technical sense, surprising to the scientists who built them. The underlying mRNA platform had been in development for more than three decades. What the pandemic did was compress a decade of manufacturing scale-up, regulatory learning, and public deployment into eighteen months — and prove, at scale, that the technology worked. The question that drives the field now is what else it can do.

## The mRNA Platform: What It Actually Is

A conventional vaccine typically introduces a weakened or killed pathogen, or a purified protein from a pathogen, to train the immune system. mRNA vaccines take a different approach: they deliver genetic instructions (messenger RNA) that cause the body's own cells to produce the target protein — in the COVID case, the spike protein — which the immune system then learns to recognize.

The key platform advantage is **programmability**. Once the infrastructure exists to design, synthesize, encapsulate, and manufacture mRNA sequences, changing the target protein is primarily a software problem. You update the RNA sequence, run it through the same manufacturing process, and produce a vaccine against a different antigen. The lipid nanoparticle (LNP) delivery system, which encapsulates the mRNA and enables cellular uptake, is largely identical across applications.

This programmability is what makes the COVID vaccine platforms interesting beyond COVID. The pipeline Moderna and BioNTech built isn't just a COVID vaccine factory — it's a general-purpose protein expression platform.

## Personalized Cancer Vaccines: The Most Significant Application

The most transformative potential application of mRNA technology is **personalized cancer vaccines**. The concept: sequence the genome of a patient's tumor, identify the specific mutations that distinguish cancer cells from healthy cells (called neoantigens), design an mRNA vaccine encoding those neoantigens, manufacture it in time to treat the patient, and train the immune system to recognize and attack the patient's specific cancer.

This is not speculative. **mRNA-4157/V940**, developed in partnership by Moderna and Merck, has produced Phase 3 trial results that represent a meaningful clinical milestone. The trial enrolled patients with high-risk resected melanoma and combined the personalized vaccine with pembrolizumab (Keytruda), a checkpoint inhibitor that prevents cancer cells from suppressing the immune response.

Results from the KEYNOTE-942 trial showed that adding mRNA-4157 to pembrolizumab reduced the risk of recurrence or death by 44% compared to pembrolizumab alone. The vaccine is manufactured in approximately 8–9 weeks from tumor biopsy to injection — fast enough to be clinically useful. Each patient's vaccine contains up to 34 neoantigens specific to their tumor.

The Phase 3 confirmatory trial (KEYNOTE-010, broader enrollment) is ongoing. If confirmed, this would represent the first personalized cancer vaccine to demonstrate survival benefit in a Phase 3 trial — a genuinely significant advance for oncology.

## Influenza: Improving on a 70-Year-Old Manufacturing Model

Seasonal flu vaccines are still produced primarily by growing influenza virus in chicken eggs — a process developed in the 1940s. The process requires six months of lead time (orders of magnitude slower than mRNA manufacturing), introduces potential mismatches between egg-adapted strains and circulating strains, and scales poorly when rapid response is needed.

mRNA flu vaccines address all three limitations. Moderna's mRNA flu vaccine (mRNA-1010) and Pfizer/BioNTech's candidate have demonstrated immunogenicity in Phase 2/3 trials. The manufacturing timeline from strain selection to product release can potentially be compressed to weeks rather than months. Crucially, the encoded antigen sequence is not modified by egg adaptation, potentially improving strain match.

The open question is efficacy versus conventional vaccines. Flu vaccination has historically been a low-efficacy intervention (40–60% effective in most seasons), partly because the seasonal selection process sometimes mismatches circulating strains. Early mRNA flu trial results have been mixed — some showing superiority to egg-based vaccines, others showing comparable efficacy. The 2025 flu season data from multiple large Phase 3 trials are expected to clarify the picture.

## HIV: The Hardest Target

HIV represents arguably the most difficult vaccine target in virology. The virus mutates rapidly, its envelope glycoprotein is heavily glycosylated (sugar-coated) in ways that shield it from antibody recognition, it integrates into the host genome, and it specifically infects the CD4+ T cells that coordinate immune responses — the cells that vaccines need to activate.

mRNA technology offers a potential path that conventional approaches cannot. The platform can encode modified immunogens — engineered versions of HIV proteins that present the broadly neutralizing epitopes (vulnerable regions) that conventional proteins would hide. Multiple mRNA-encoded immunogens can be delivered in sequence, potentially "guiding" the immune system through a maturation process to generate the broadly neutralizing antibodies needed for protection.

IAVI and Moderna have published Phase 1 results showing that an mRNA HIV vaccine targeting the gp120 protein can induce broadly neutralizing antibody precursors in 97% of recipients — an immunological milestone that prior approaches could not achieve. Moving from inducing precursor cells to inducing durable broadly neutralizing antibodies at protective titers remains the central scientific challenge.

## RSV: The First Post-COVID mRNA Win

While the cancer vaccine and HIV programs represent longer-term potential, the **RSV mRNA vaccines** represent the first confirmed post-COVID mRNA success in a new indication. RSV (respiratory syncytial virus) causes approximately 160,000 hospitalizations per year in adults over 60 in the United States.

Moderna's mRESVIA (mRNA-1345) became the first mRNA vaccine approved for an indication other than COVID when the FDA granted approval in May 2024 for adults 60 and older. Clinical trials showed 83% efficacy against lower respiratory tract disease in the first RSV season — comparable to Pfizer's and GSK's protein-based RSV vaccines that were approved around the same time.

The approval validated that the mRNA platform could work across different viral targets, not just the unusually favorable spike protein of SARS-CoV-2.

## Manufacturing Scalability: What Changed Since 2020

One of the less-discussed advances driven by COVID-scale deployment is **manufacturing process maturity**. In 2020, manufacturing mRNA at clinical scale required expensive manual steps, had high batch failure rates, and used processes that couldn't easily scale. The demand for hundreds of millions of COVID vaccine doses forced rapid process engineering.

Key improvements:
- **In vitro transcription (IVT) yields**: Enzyme and process optimization has increased RNA yield per batch substantially, reducing cost
- **LNP encapsulation**: Microfluidic mixing processes have become more reliable and scalable, improving encapsulation efficiency and batch-to-batch consistency
- **Cold chain improvements**: Modified nucleoside chemistry (used in the approved vaccines) now allows standard refrigeration stability for months rather than ultra-cold storage

The result is that the cost per dose of manufacturing mRNA vaccines has fallen dramatically since 2021, and the manufacturing infrastructure exists at a scale that simply didn't exist five years ago.

## The Regulatory Precedent

The COVID approval process established regulatory pathways that benefit the entire mRNA field. The FDA's familiarity with mRNA vaccine biology, the safety monitoring infrastructure built around COVID vaccination, and the data frameworks for evaluating mRNA products all reduce the regulatory friction for subsequent applications.

The personalized cancer vaccine presents unique regulatory challenges — it is simultaneously a manufacturing process and a pharmaceutical product, with each patient's vaccine being technically a distinct product. The FDA has worked with Moderna on a regulatory framework for individualized neoantigen therapy that would allow streamlined approval of each patient's vaccine under a master manufacturing approval.

The next decade of mRNA medicine will likely be characterized less by dramatic biological breakthroughs and more by the methodical expansion of the platform across disease areas where it offers genuine advantages: rapid response to emerging pathogens, personalized oncology, targets that conventional protein manufacturing cannot address. The platform is proven. The question is how broadly it applies.

mRNA Technology: What Comes After the COVID Vaccine

// COMMENTS

ON THIS PAGE